Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch

4d ago, source:

Soleno Therapeutics, Inc.'s New Drug Application filing of DCCR for the treatment of patients with Prader-Willi Syndrome ...

Soleno Therapeutics, Inc. Common Stock (SLNO) Short Interest

1mon ago, source: Nasdaq

Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to indicate market sentiment and gauge the stock ...

Soleno Therapeutics Inc SLNO

18d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SLNO Soleno Therapeutics, Inc.

4d ago, source: Seeking Alpha

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate ...

Soleno Therapeutics Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome

3d ago, source:

C602 an open-label extension study enrolled participants who completed DESTINY PWS (C601), an international, multi-center, randomized, double-blind, placebo-controlled study of DCCR in 127 PWS ...

Soleno Therapeutics Shares Rise 37% After Breakthrough Designation for Diazoxide Choline

4d ago, source:

By Chris Wack Soleno Therapeutics were trading near a three-year high after the Food and Drug Administration granted breakthrough therapy designation ...